Engineered immune cells join forces with biologic drug to attack advanced breast cancer
NCT ID NCT06878248
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This early-stage study tests a new two-part treatment for people with advanced breast cancer that has not responded to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of an antibody-based drug (ABBV-461). The main goals are to check safety, find the best doses, and see if the combination can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.